Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

It’s Never Too Late to Quit Drinking Alcohol

by Team Lumida
October 21, 2025
in Health and Longevity
Reading Time: 3 mins read
A A
0
It’s Never Too Late to Quit Drinking Alcohol
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

Powered by lumidawealth.com

  • Long-term daily drinking into older age compounds health risks as alcohol metabolizes more slowly; even “moderate” intake can escalate without firm guardrails.
  • Medical guidance for seniors typically caps consumption at seven drinks/week; adherence is hard due to ingrained habits and coping needs (loneliness, grief, anxiety).
  • Quitting in later life still delivers tangible benefits: better sleep, cognition, mood stability, and lower accident/medication-interaction risks—often with support improving success rates.

What Happened?

A 72-year-old writer recounts five decades of nightly drinking that evolved from hard liquor to wine, rationalized as “only evenings.” A doctor’s warning on emerging heart issues triggered a limit attempt that quickly slipped, prompting a cold-turkey quit shortly before age 72. Early withdrawal brought mood swings and marital strain, but over 21 months sobriety yielded clearer thinking, improved sleep, and renewed appreciation for life. The essay underscores NIH guidance for older adults (track drinks, plan alcohol-free days) and highlights that professional treatment boosts success odds, given higher sensitivity to alcohol and polypharmacy in seniors.

Why It Matters

For individuals and caregivers, the piece reinforces that late-life cessation meaningfully reduces health risks (falls, fractures, hypertension, diabetes exacerbation, adverse drug interactions) and improves quality of life. For employers, insurers, and healthcare systems, supporting senior-focused alcohol-use interventions can lower acute care incidents and medication complications. Behavioral inertia is a key hurdle: decades-long routines and using alcohol to cope require structured strategies (medical consults, counseling, community programs) rather than willpower alone.

What’s Next?

  • Practical steps: physician consults, intake tracking, explicit weekly limits, scheduled alcohol-free days, and evaluating counseling/outpatient/residential programs for support.
  • Risk management: medication reviews for interactions, home safety checks to reduce fall/fire risk, and social alternatives to address loneliness or grief triggers.
  • Measurement: monitor sleep quality, mood, BP/glucose control, and incident rates (falls/ER visits) to quantify benefits and maintain motivation.
Source
Previous Post

Chinese Battery Giant CATL Delivers Solid Earnings

Next Post

BlackRock Is Pulling Bitcoin Whales Into Wall Street’s Orbit

Recommended For You

GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

by Team Lumida
3 days ago
GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

As 13 million Americans take GLP-1 drugs like Ozempic and Mounjaro, a growing body of research warns the drugs can cause up to 10% lean muscle loss —...

Read more

Hospital at Home Linked to Lower Mortality and Fewer ER Visits, JAMA Study Finds

by Team Lumida
1 week ago
dextrose hanging on stainless steel IV stand

A new JAMA Network Open study of Medicare data shows hospital-at-home programs reduce in-hospital mortality, ED visits, and ICU escalations — but adoption is concentrated in urban hospitals...

Read more

8 Evidence-Based Tips for Healthy Eating, According to the NHS

by Team Lumida
1 week ago
vegetable salad

From starchy carbs to salt limits, the UK's National Health Service lays out the practical fundamentals of a balanced diet — and most adults are still getting it...

Read more

The FDA Is Fast-Tracking Psychedelics. The Infrastructure to Support Them Isn’t Ready.

by Team Lumida
2 weeks ago
Abstract colorful psychedelic swirling patterns

Trump's executive order to accelerate psychedelic drug development is welcome — but Bloomberg Opinion's Lisa Jarvis warns the ketamine clinic free-for-all is a cautionary tale the FDA must...

Read more

Ultrasound on a Chip: Butterfly Network’s $4,000 Device Is Taking Medical Imaging Global

by Team Lumida
3 weeks ago
a person holding a tablet

Butterfly Network's semiconductor-based handheld ultrasound costs a fraction of traditional machines and has reached 150,000 deployments worldwide, pairing AI with imaging to put diagnostics in the hands of...

Read more

Nearly 1 in 8 Americans Now Uses Sleep Aids — and Pharma Is Taking Notice

by Team Lumida
3 weeks ago
woman sleeping on bed under blankets

A new federal study finds 13% of U.S. adults rely on prescription drugs, OTC supplements, marijuana, or CBD to sleep, as Eli Lilly's $7.8B acquisition of a sleep...

Read more

Amazon One Medical Launches GLP-1 Weight Loss Program at $25 a Month

by Team Lumida
3 weeks ago
Amazon Targets Rural America: A Game-Changer for Delivery Services

Amazon One Medical is rolling out a weight management program that includes GLP-1 medications, offering compounded pills starting at $25/month with same-day delivery in 3,000 cities.

Read more

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
1 month ago
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

Melatonin is generally safe for short-term use and non-habit-forming, but it carries real side effects and drug interactions that most users overlook — Mayo Clinic breaks down what...

Read more

How Much Muscle Should You Have — and What Happens When You Lose It?

by Team Lumida
1 month ago
diagram

Muscle mass averages, why they matter for long-term health, and what the science says about measuring and building skeletal muscle across every age group.

Read more

AI Scribes Save Clinicians 13–16 Minutes a Day — and Boost Visit Volume by 1.7%, Study Finds

by Team Lumida
1 month ago
AI Investment Boom: How Tech Giants Are Leading the Charge

The largest study of AI scribe adoption to date — 8,500+ clinicians across five academic medical centers — found the tools cut EHR time by 3% and documentation...

Read more
Next Post
Is BlackRock the New Leader in Alternative Investments?

BlackRock Is Pulling Bitcoin Whales Into Wall Street’s Orbit

Pop Mart Sales Top Market Expectation, Signal Sustained Momentum

Pop Mart Sales Top Market Expectation, Signal Sustained Momentum

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Qatar’s Wealth Fund Backs Anthropic in $183B Valuation Round, Deepening AI Push

Anthropic Takes Direct Shot at OpenAI as AI Chatbots Clash Over Ads and Trust

February 5, 2026
Johnson & Johnson Strikes Deal with Trump for Drug Discounts and Tariff Relief

Johnson & Johnson Strikes Deal with Trump for Drug Discounts and Tariff Relief

January 9, 2026
China’s Bold Economic Moves: What You Need to Know Now

China’s Economy Shows Broad-Based Slowdown in July, Raising Pressure for More Stimulus

August 15, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018